Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.

Yi-Jiun Su , Anne Marijn Kramer , Mark P Hamilton , Neha Agarwal , Hrishikesh K Srinagesh , John H Baird , Bita Sahaf , Adam Kuo , Zachary J Ehlinger , Moksha H Desai , Skyler P Rietberg , Ramya Tunuguntla , Shabnum Patel , Harshini Chinnasamy , Nikolaos Gkitsas-Long , Dorota D Klysz , Annie Kathleen Brown , Sushma Bharadwaj , Saurabh Dahiya , Melody Smith

Cancer Discov

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.

Published: April 2025

Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964843	PMC
http://dx.doi.org/10.1158/2159-8290.CD-24-1071	DOI Listing

Publication Analysis

Top Keywords

car t-cell

clinical outcomes

tcm cells

tem cells

cd8+ tcm

effects initial

initial anti-cd19

anti-cd19 car

t-cell therapy

therapy subsequent

A PHP Error was encountered